Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 3/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 4/20 | 0.42 |
| ▸ | LIPE | Q05469 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5520664 | 1.00 | HDAC1 (0.48) | HDAC1HDAC2TACR1USP30RORC | |
| SCHEMBL3177397 | 0.88 | GPR119 (0.50) | TACR1USP30RORCLIPEGPR119 | |
| SCHEMBL13461072 | 0.88 | GPR119 (0.50) | TACR1USP30RORCLIPEGPR119 | |
| SCHEMBL13433734 | 0.88 | GPR119 (0.50) | TACR1USP30RORCLIPEGPR119 | |
| SCHEMBL3180166 | 0.82 | TACR1 (0.44) | TACR1 | |
| SCHEMBL5989023 | 0.82 | TACR1 (0.44) | TACR1 | |
| SCHEMBL3172844 | 0.82 | TACR1 (0.44) | TACR1 | |
| SCHEMBL3181798 | 0.82 | TACR1 (0.44) | TACR1 | |
| SCHEMBL3184361 | 0.82 | TACR1 (0.44) | TACR1 | |
| SCHEMBL3177278 | 0.82 | TACR1 (0.44) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | HDAC1 1895/4885HDAC2 2006/4885TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.